Fig. 2.

Inhibitory effect of the ERRα antagonist chlordane (chl) on aromatase expression and its promoter activity in PGE2-treated prostate stromal cells. A, WPMY-1 cells were pretreated for 30 min with or without 10 μm chlordane and treated with PGE2. After 24 h or 48 h, total RNA or protein was extracted and real-time RT-PCR or Western blot was performed, respectively. A, Upper panel, Real-time RT-PCR. Values represent mean ± sd (n = 4). **, P < 0.01 compared with untreated controls. A, Lower panel, Western blot analysis was performed using antibodies to aromatase or GAPDH. The experiments were performed in duplicate. Similar results were obtained from separate experiments. B, Cells were transfected with aromatase promoter luciferase reporter plasmid in 24-well plates for 6 h and pretreated with vehicle or chlordane (10 μm) for 30 min and then treated with PGE2 (1 μm) for 24 h. Luciferase activity was measured using dual-luciferase assay and normalized to the control renilla luciferase activity. Values represent mean ± sd (n = 4). *, P < 0.05 compared with untreated controls.